MindMed Board Battle Continues with Competing Shareholder Bids

May 5, 2023 · Green Market Report

Both parties accused each other of not understanding FDA processes.

After psychedelic drug company Mind Medicine (Nasdaq: MNMD) released a detailed letter to shareholders pushing back against an attempted board coup by a company called FCM MM Holdings, FCM responded with its own letter to shareholders accusing the current board of botching the company’s strategy as well as other misdeeds.

FCM MM Holdings and its affiliates beneficially own 1,368,538 common shares of MindMed Inc., representing approximately 3.5% of the outstanding common shares.

MindMed released its letter alongside its earnings earlier this week.

FCM’s letter notes that MindMed’s stock valuation has plunged 95%, while the executive team awarded itself with lavish compensation. It’s worth noting that the PSYK ETF is down 22% for the past year and the Horizons Psychedelic Stock ETF is down 42% for the past year.

FCM says that the board only spent 12.7% of its funds on operating costs for the company’s drugs and 31.8% on compensation. It also accuses the board of only owning 0.22% of the company’s shares, which it claims to be smaller than most boards’ average.

The FCM letter suggests that its suggested board members would cut unnecessary expenses and save the company $4.5 million. It also wants to proceed with a Phase 3 study of MM-120. The group believes that the company is pursuing a Phase 2b dose finding study that is flawed and unnecessary. The current MindMed board stated it can’t proceed to the Phase 3 study without completing this Phase 2b study.

The letter also claims that the current board doesn’t have experience with the FDA process, which the current board has accused the FCM team of as well.

The FCM team did disclose it has met with the current MindMed team but hasn’t gotten the response it had hoped for.

“Since 2021, we have attempted to engage constructively with the Board on our ideas for adding value for the benefit of all MindMed shareholders, including our Value Enhancement Plan that we presented to the Board and management in August 2022,” the letter read. “We remain dumbstruck by the Board’s lack of urgency in addressing the critical issues we raised with them. Unfortunately, we had to take the extraordinary step of nominating four highly qualified director candidates because FCM determined that the only way to put MindMed back on track and stop the destruction of further shareholder value would be to reconstitute the Board and take immediate action for the benefit of all shareholders.” (Full Story)

In categories:Business Psychedelics
Next Post

Connecting Cannabis Brands and Consumers: The Future of Brand Discovery

THE CANNABIS INDUSTRY has been rapidly expanding in recent years, with legal status and widespread acceptance paving the way for significant growth and diversification. As the industry evolves, the role of technology in connecting cannabis brands directly with consumers is becoming increasingly important.…
Previous Post

The $300,000,000 Club - Which 5 States Collected over $300 Million in Cannabis Tax Revenue Last Year Alone?

A recent report from the Marijuana Policy Project revealed that tax revenue from adult-use cannabis experienced a decline across legal states in 2022, marking the first time this has occurred in the United States. While sales tax from cannabis still generated a respectable…
Random Post

Seth Rogen Says No to Edibles in Interview with Bill Gates

As the first guests on Unconfuse Me with Bill Gates, Seth Rogen and his wife Lauren Miller Rogen discuss Hilarity for Charity, their fundraising organization that focuses on Alzheimer's. But the conversation gets really interesting when Gates asks the Rogens about…
Random Post

Marijuana Rescheduling Would ‘Supersize’ The Industry, Former DEA Heads And White House Drug Czars Warn Biden Administration

Six former Drug Enforcement Administration (DEA) heads and five former White House drug czars have sent a letter to the attorney general and current DEA administrator, voicing opposition to the top federal health agency’s recommendation to reschedule marijuana. They also…
Random Post

Virginia Gov. Proposes CBD Carveout for Crackdown on Hemp-Based THC Products

Virginia Gov. Glenn Youngkin (R) is proposing a CBD carveout to a proposed state law that would enact strict regulations on hemp-derived THC products, the Virginia Mercury reports. Under the governor’s plan, hemp products that contain a 25:1 ratio of CBD to THC would…
Random Post

German Lawmakers Hold First Debate On Marijuana Legalization Bill

German lawmakers have officially begun consideration of a bill that would legalize marijuana nationwide. The country’s parliament, called the Bundestag, held the first debate on the legislation on Wednesday after delaying the meeting last week due to the conflict in Israel…